Serum Level of sRAGE (Soluble Receptor for Advanced Glycation end Products) in the Most Common Lung Diseases in Childhood

Serum Level of sRAGE (Soluble Receptor for Advanced Glycation
End Products) in the Most Common Lung Diseases in Childhood

Abstract

Background. The soluble form of the receptor for advanced glycation end products (sRAGE) is both a
marker and a participant in the pathophysiology of a number of lung diseases. The present study evaluates the value of sRAGE as a biomarker for early lung damage in the most common pediatric pulmonary diseases.
Methods. In this study were enrolled 185 children from 2 months to 17 years old, hospitalized in the
Pediatric Clinic, Aleksandrovska, with acute respiratory symptoms, divided according to etiology, as follows – bronchiolitis – the first episode of wheezing up to 2 years, two episodes of wheezing up to 2 years of age, recurrent wheezers defined as ≥ 3 episodes up to 3 years of age, asthma in children over 5 years, pneumonia with consolidation, cystic fibrosis, and a control group. An anamnesis, physical examination, blood sample, and thoracic ultrasound were performed. The serum concentration of sRAGE was investigated by ELISA methodology.
Results. We detected decreased sRAGE concentration in children with a family history of asthma
(p=0.04) and severe obstruction with the necessity of oxygen supplementation (p=0.002). There was a
significant inverse age correlation – sRAGE in serum decline with age (p=0.005). Children with asthma had
the lowest levels of sRAGE – 514.49 pg/mL, followed by those with recurrent wheezing- which levels were
twice lower than controls (578.73 vs. 1071.28 pg/mL, p=0.001) and statistically significantly decreased compared to the first episode of wheezing (589.44 vs.911.50 pg/mL, p=0.05).
Conclusions. Children with lower sRAGE are prone to more severe clinical presentation, risk for
recurrent wheezing, and asthma due to a deficiency in its anti-inflammatory effect.
“Financial support by GRANT 173/2022 MU – Sofia”
Key words: sRAGE, wheezing, asthma

Bibliography

1. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267(21):14998‐15004.
2. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003; 370:1097–109.
3. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. Journal of molecular medicine. 2005; 83:876–86.
4. Shirasawa M, Fujiwara N, Hirabayashi S, et al. Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells. 2004;9:165–174.
5. Reynolds PR, Stogsdill JA, Stogsdill MP, et al.  Up-Regulation of RAGE by Alveolar Epithelium Influences Cytodifferentiation and Causes Severe Lung Hypoplasia. Am J Respir Cell Mol Biol. 2011; 45(6):1195-202.
6. Lizotte PP, Hanford LE, Enghild JJ, et al.  Developmental expression of the receptor for advanced glycation end-products (RAGE) and its response to hyperoxia in the neonatal rat lung. BMC Dev Biol. 2007; 7:15.
7. Egron, C., Roszyk, L., Rochette, E., et al.   Serum Soluble Receptor for Advanced Glycation End-Products during Acute Bronchiolitis in Infant: Prospective Study in 93 Cases. Pediatr. Pulmonol. 2018, 53, 1429–1435.
8. Lyu, Y., Zhao, H., Ye, Y., et al. Decreased Soluble RAGE in Neutrophilic Asthma Is Correlated with Disease Severity and RAGE G82S Variants. Mol. Med. Rep. 2018, 17, 4131–4137.
9. Patregnani J.T., Fujiogi M., Camargo C.A, et al. Serum Soluble Receptor for Advanced Glycation End Products in Infants With Bronchiolitis: Associations With Acute Severity and Recurrent Wheeze. Clin Infect Dis. 2021 Nov 1; 73(9): e2665–e2672.
10. Miller A.L, Sims G.P. Brewah Y.A, et al., Opposing Roles of Membrane and Soluble Forms of the Receptor for Advanced Glycation End Products in Primary Respiratory Syncytial Virus Infection. J Infect Dis. 2012 Apr 15; 205(8): 1311–1320.
11. Brandt E.B., LewkowichIan P. RAGE-induced asthma: A role for the receptor for advanced glycation end-products in promoting allergic airway disease. The Journal of allergy and clinical immunology 2019; 144(3):651-653.
12. El-Seify, M.Y.H.; Fouda, E.M.; Nabih, E.S. Serum Level of Soluble Receptor for Advanced Glycation End Products in Asthmatic Children and Its Correlation to Severity and Pulmonary Functions. Clin. Lab. 2014, 60, 957–962.
13. Sukkar MB, Wood LG, Tooze M, et al. Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J 2012;39:721-729.
14. Montserrat Sierra-Colomina , Alberto García-Salido , Inés Leoz-Gordillo. sRAGE as severe acute bronchiolitis biomarker, prospective observational study. Pediatr Pulmonol. 2020 Dec;55(12):3429-3436.
15. Mauri T, Masson S, Pradella A, et al. Elevated plasma and alveolar levels of soluble receptors for advanced glycation end products are associated with severity of lung dysfunction in ARDS patients. Tohoku J Exp Med. 2010;222(2):105‐112.
16. Makam M, Diaz D, Laval J, et al. Activation of critical, hostinduced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs. Proc Natl Acad Sci U S A. 2009; 106:5779–83.
17. Foell D, Seeliger S, Vogl T, et al. Expression of S100A12 (ENRAGE) in cystic fibrosis. Thorax. 2003; 58:613–7.
18. Milutinovic PS, Alcorn JF, Englert JM, et al. The receptor for advanced glycation end products is a central mediator of asthma pathogenesis. Am J Pathol. 2012; 181:1215–25.
19. Iannitti RG, Casagrande A, De Luca A, et al. Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis. Am J Respir Crit Care Med. 2013; 188:1338–50.

Address for correspondence:

Department of Pediatrics, “Alexandrovska” Hospital,
MU – Sofia

1, “Georgi Sofiisy”, Str.
1431, Sofia, Bulgaria
e-mail: gal_ps@yahoo.co.uk